Morten Salomo

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Sonja Zweegman, Bronno van der Holt, Ulf‐Henrik Mellqvist et al. · Blood · 2016 · 111 citations · Full text

Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo et al. · European Journal Of Haematology · 2015 · 68 citations · Full text

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau et al. · Leukemia · 2020 · 60 citations · Full text